Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Onward Medical   /   Forum Onward Medical geopend

Aandeel ONWARD MEDICAL BRU:ONWD.BL, NL0015000HT4

Laatste koers (eur) Verschil Volume
5,120   +0,100   (+1,99%) Dagrange 4,950 - 5,120 30.438   Gem. (3M) 60,8K

Forum Onward Medical geopend

Volgen
1.630 Posts
Pagina: «« 1 2 3 4 5 6 ... 82 »» | Laatste | Omlaag ↓
  1. Renno54 30 juni 2022 19:36
    Dank je voor het plaatsen Voda.

    Weer een mooi p.b. Van Onward. Een redelijk onbekend beurs genoteerd bedrijf met, naar ik verwacht, een mooi vooruitzicht.
    Hetis te hopen voor de mensen met verlamming verschijnselen dat er nog meer positieve resultaten worden behaald in de nabije toekomst.
    Duimpje geplaatst;))
  3. forum rang 4 Hercule Poirot 18 juli 2022 11:39
    Ik heb sinds mijn vorige melding mijn positie weer iets uitgebreid naar 3275 stuks. Op deze niveau's blijf ik kleine aankopen doen. Komende maanden kunnen we waarde creërend nieuws verwachten volgens Marver.
    Buiten het feit dat de betere mobiliteit van personen met een dwarslaesie natuurlijk erg belangrijk is, mis ik wel een soort van waardeperspectief voor de toekomst. Stel dat deze behandelingen het maken wat zijn dan de potentiële opbrengsten?
  4. Renno54 20 juli 2022 09:49
    At ONWARD, our team continues to work hard to develop therapies that can make a meaningful difference in the lives of people with spinal cord injury. Recent weeks have delivered the following achievements:

    Completion of enrollment in the LIFT Home Study
    We announced in early June that we had completed enrollment in the LIFT Home Study. This trial is designed to study the safety and performance of ARCEX Therapy when used in the home. The study enrolled 17 participants at five leading research centers in the US: Craig Hospital in Denver, Colorado, Shepherd Center in Atlanta, Georgia, Spaulding Research Institute in
    Boston, Massachusetts, University of Minnesota, and the University of Washington. Participants are followed for four weeks to assess whether continued access to ONWARD’s ARCEX Therapy is safe and can be used to enhance long-term benefit.

    The LIFT Home Study is a successor to ONWARD’s Up-LIFT Study, a pivotal trial that completed enrollment of 65 participants in December 2021, with participating research centers in the US, Canada, the UK, and Europe. Up-LIFT is designed to demonstrate ONWARD ARCEX Therapy can improve the strength and function of upper limbs when used in the rehabilitation clinic setting.

    Completing these studies is a major step toward the commercialization of ARCEX Therapy for restoration of hand and arm function as expected in 2023. You can learn more here.
    Release of “Onward with Scott Chesney” Interview with Erica Coulston
    As part of ONWARD’s continuing effort to engage with and learn from the SCI community, Scott Chesney released another in his interview series with leading SCI stakeholders. Erica Coulston, Co-Founder and President of Walk the Line shares her journey as a C6/7 quadriplegic and discusses her interest in potential therapies to restore blood pressure.
    As you may recall, ONWARD is working to develop, investigate, and potentially commercialize therapy to address orthostatic hypotension. Watch the interview and subscribe to the series on ONWARD’s YouTube channel.

    We expect several important developments later this summer and fall. I will be sure to keep you posted.

    Best wishes,

    Dave

    Dave Marver
    CEO
  5. Renno54 20 juli 2022 09:51
    At ONWARD, our team continues to work hard to develop therapies that can make a meaningful difference in the lives of people with spinal cord injury. Recent weeks have delivered the following achievements:

    Completion of enrollment in the LIFT Home Study
    We announced in early June that we had completed enrollment in the LIFT Home Study. This trial is designed to study the safety and performance of ARCEX Therapy when used in the home. The study enrolled 17 participants at five leading research centers in the US: Craig Hospital in Denver, Colorado, Shepherd Center in Atlanta, Georgia, Spaulding Research Institute in
    Boston, Massachusetts, University of Minnesota, and the University of Washington. Participants are followed for four weeks to assess whether continued access to ONWARD’s ARCEX Therapy is safe and can be used to enhance long-term benefit.

    The LIFT Home Study is a successor to ONWARD’s Up-LIFT Study, a pivotal trial that completed enrollment of 65 participants in December 2021, with participating research centers in the US, Canada, the UK, and Europe. Up-LIFT is designed to demonstrate ONWARD ARCEX Therapy can improve the strength and function of upper limbs when used in the rehabilitation clinic setting.

    Completing these studies is a major step toward the commercialization of ARCEX Therapy for restoration of hand and arm function as expected in 2023. You can learn more here.
    Release of “Onward with Scott Chesney” Interview with Erica Coulston
    As part of ONWARD’s continuing effort to engage with and learn from the SCI community, Scott Chesney released another in his interview series with leading SCI stakeholders. Erica Coulston, Co-Founder and President of Walk the Line shares her journey as a C6/7 quadriplegic and discusses her interest in potential therapies to restore blood pressure.
    As you may recall, ONWARD is working to develop, investigate, and potentially commercialize therapy to address orthostatic hypotension. Watch the interview and subscribe to the series on ONWARD’s YouTube channel.

    We expect several important developments later this summer and fall. I will be sure to keep you posted.

    Release of “Onward with Scott Chesney” Interview with Erica Coulston
    As part of ONWARD’s continuing effort to engage with and learn from the SCI community, Scott Chesney released another in his interview series with leading SCI stakeholders. Erica Coulston, Co-Founder and President of Walk the Line shares her journey as a C6/7 quadriplegic and discusses her interest in potential therapies to restore blood pressure.
    As you may recall, ONWARD is working to develop, investigate, and potentially commercialize therapy to address orthostatic hypotension. Watch the interview and subscribe to the series on ONWARD’s YouTube channel.

    We expect several important developments later this summer and fall. I will be sure to keep you posted.

    Best wishes,

    Dave

    Dave Marver
    CEO

    Best wishes,

    Dave

    Dave Marver
    CEO
  6. [verwijderd] 7 augustus 2022 21:19
    Een nieuwe positieve update zou mooi zijn. Of was dit al het nieuws dat we mochten verwachten deze zomer? Ik geloof echt in dit aandeel omwille van de reeds bewezen resultaten, maar begin er toch aan te twijfelen of het al uitgebodemd is. Hebben die investeerders aan IPO prijs aangekocht?
  7. forum rang 4 Hercule Poirot 15 augustus 2022 11:00
    quote:

    Dark_enRahl schreef op 7 augustus 2022 21:19:

    Een nieuwe positieve update zou mooi zijn. Of was dit al het nieuws dat we mochten verwachten deze zomer? Ik geloof echt in dit aandeel omwille van de reeds bewezen resultaten, maar begin er toch aan te twijfelen of het al uitgebodemd is. Hebben die investeerders aan IPO prijs aangekocht?
    Het is inderdaad al een tijdje stil. Volgens de CEO zouden er nog enkele nieuwsberichten naar buiten komen in de periode juli t/m december 2022. Een update over lopende onderzoeken bijvoorbeeld. Vwb de investeerders ga ik er vanuit dat ze niet veel lager ingestapt zijn dan de huidige beurskoers. Vanaf het hoogtepunt is er al 8 euro verdwenen, meer dan een halvering.
    De cijfers over kwartaal 2 zullen binnenkort ook wel verschijnen?
  8. Renno54 16 augustus 2022 11:25
    Hieronder een stukje uit de laatste nieuwsbrief van Onward Medical

    As you may recall, ONWARD is working to develop, investigate, and potentially commercialize therapy to address orthostatic hypotension. Watch the interview and subscribe to the series on ONWARD’s YouTube channel.

    We expect several important developments later this summer and fall. I will be sure to keep you posted.

    Best wishes,

    Dave

    Dave Marver

    CEO

    Verder komen de half jaar cijfers op 27 September.
  11. [verwijderd] 30 augustus 2022 20:19
    Competing with other innovative Swiss SMEs, ONWARD has won a Sino-Swiss Business Incubation award in the HealthTech category. Winners of this #SSBI program receive resources and financial support to establish partnerships and determine market-entry strategies for China. We thank SSBICom,  Swiss-Chinese Chamber of Commerce (SCCC), and Innovaud for their support.
  14. Renno54 8 september 2022 21:50
    ONWARD Announces Participation at Upcoming Investor Events in September
    EINDHOVEN, the Netherlands & LAUSANNE, Switzerland—September 7, 2022--ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury (SCI), today announced that management will participate in the following upcoming investor events in September:
    • KBC Securities Virtual Life Sciences Conference
    September 16, 2022
    Dave Marver, CEO, and Lara Smith Weber, CFO, will participate in the conference and give a company presentation.
    • btov Portfolio Day
    September 21, 2022
    Berlin, Germany
    Lara Smith Weber, CFO, will give a company presentation.
    Information on upcoming conferences is available in the investor section of the ONWARD website at ir.onwd.com/news-events.
  15. Renno54 8 september 2022 21:54
    About ONWARD Medical
    ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. ONWARD has received three Breakthrough Device Designations from the U.S. FDA, encompassing both ARC-IM and ARC-EX. ARC-EX is an external, non- invasive platform consisting of a wearable stimulator and wireless programmer. The company’s first pivotal trial, called Up-LIFT, evaluating the ability of ARCEX Therapy to improve upper extremity strength and function, completed enrollment in December 2021 with 65 subjects worldwide. Topline results are expected in September 2022. ARC-IM consists of an implantable pulse generator and lead placed near the spinal cord. The company completed its first-in-human use of the ARC-IM neurostimulator in May 2022
  20. forum rang 10 voda 13 september 2022 07:50
    Positieve studieresultaten Onward
    Lancering in tweede helft 2023.

    (ABM FN-Dow Jones) Onward Medical heeft positieve resultaten geboekt met een studie naar het herstellen van de arm- en handfunctie van mensen die lijden aan ruggengraatletstel. Dit maakte het bedrijf dinsdagochtend bekend.

    Het primaire eindpunt op het vlak van effectiviteit werd met de studie behaald.

    "Het herstellen van de hand- en armfunctie na een dwarslaesie is levensveranderend", aldus Onward.

    Inmiddels is Onward druk bezig met het voorbereiden van de aanvragen bij de toezichthouders en de lancering in de VS en Europa. CEO Dave Marver denkt dat dit in de tweede helft van 2023 zou moeten lukken.

    Door: ABM Financial News.

    info@abmfn.nl

    Redactie: +31(0)20 26 28 999
1.630 Posts
Pagina: «« 1 2 3 4 5 6 ... 82 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

ONWARD MEDICAL Nieuws

  1. Technologie van Onward geprezen door TIME Magazine
  2. Onward Medical haalt 50 miljoen euro op
  3. Onward lanceert nieuwe kapitaalverhoging
  4. Onward Medical vernieuwt bestuur
  5. Beursblik: Degroof Petercam ziet meer potentieel in koers Onward Medical
  6. Onward Medical verwerft exclusieve rechten op gedachtegestuurde technologie
  7. Onward Medical krijgt ook notering aan Euronext Parijs
  8. Onward Medical kondigt nieuwe succesvolle implantatie aan
  9. Iets meer in kas bij Onward Medical
  10. Belang Wellington in Onward gehalveerd